Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
J Infect Dis
; 225(5): 820-824, 2022 03 02.
Article
en En
| MEDLINE
| ID: mdl-34746954
ABSTRACT
BACKGROUND:
Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.METHODS:
We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.RESULTS:
Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.CONCLUSIONS:
The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inmunodeficiencia Variable Común
/
Enfermedades de Inmunodeficiencia Primaria
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
/
Anticuerpos Antivirales
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
J Infect Dis
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia